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AstraZeneca, Lund, SwSummary Adherence to maintenance therapy is often poor in patients with
asthma. Simplifying dosing regimens has the potential to improve both adherence
and asthma-related morbidity. In this 12-week, randomized, double-blind, double-
dummy, parallel-group study, 617 patients with mild to moderate persistent asthma
(mean forced expiratory volume in 1 s [FEV1] 78.5% predicted) who were not
optimally controlled on inhaled corticosteroids (200–500 mg/day) were randomized
to once-daily budesonide/formoterol (80/4.5 mg, 2 inhalations in the evening),
twice-daily budesonide/formoterol (80/4.5 mg, 1 inhalation), or a corresponding
dose of budesonide once-daily (200 mg, 1 inhalation in the evening). All patients
received budesonide (100 mg twice daily) during a 2-week run-in. Changes in mean
morning peak expiratory flow (PEF) were similar for od budesonide/formoterol
(23.4 l/min) and twice-daily budesonide/formoterol (24.1 l/min), and both were
greater than with budesonide (5.5 l/min; both Po0.001). Evening PEF, symptom-free
days, reliever-free days, and asthma control days were improved with budesonide/Elsevier Ltd. All rights reserved.
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P. Kuna et al.2152formoterol therapy vs. budesonide (Po0.05 vs. budesonide for all variables). All
treatments were well tolerated. Budesonide/formoterol administered once daily in
the evening is a convenient treatment regimen that is as effective in improving
asthma control as twice-daily dosing in patients with mild to moderate persistent
asthma.
& 2006 Elsevier Ltd. All rights reserved.Introduction
Combination therapy with inhaled corticosteroids
(ICS) and long-acting b2-agonists is well established
as maintenance treatment for patients with asthma
that is not optimally controlled on ICS alone.1,2 This
may require the use of several inhalers, i.e. an ICS
inhaler plus a long-acting b2-agonist inhaler for
maintenance, in addition to a short-acting b2-
agonist for reliever medication. Such regimens
can be too complicated for some patients, many
of whom prefer simple treatments using the
minimum number of devices and less frequent
dosing.3,4 Treatment regimens that address these
issues have the potential to improve adherence and
reduce the morbidity associated with asthma.
The co-administration of an ICS and a long-acting
b2-agonist in the same inhaler is an important
advance in asthma medication that simplifies drug
administration. The combination of budesonide and
formoterol (Symbicorts Turbuhalers) has been
shown to be effective and well tolerated in a range
of patient populations.5–8 In addition, greater
efficacy of a lower dose of ICS in conjunction with
a long-acting b2-agonist (budesonide/formoterol
80/4.5 mg twice daily), compared with a higher
dose of ICS alone, has been demonstrated in
patients with mild to moderate asthma.9 Budeso-
nide/formoterol used as maintenance plus as
needed for symptom relief has also been shown to
be efficacious and well tolerated.10
Another factor that affects patients’ adherence
to prescribed medication is dosing frequency.
Adherence to asthma therapy increases with less-
frequent dosing regimens11 and once-daily dosing
may thus aid adherence. Buhl et al.12 have shown
once-daily dosing with budesonide/formoterol
(160/4.5 mg, 2 inhalations in the evening) to be an
effective treatment for patients with moderate
persistent asthma. Morning and evening peak
expiratory flow (PEF), night-time awakenings,
symptom-free days, reliever-free days, and asthma
control days were all improved compared with a
corresponding dose of budesonide alone and the
improvements were comparable with twice-daily
budesonide/formoterol (160/4.5 mg, 1 inhalation in
the morning and evening). Once-daily budesonide/formoterol provided sustained efficacy over 24 h
that was comparable with twice-daily dosing and
was superior to budesonide alone.
Once-daily dosing may be particularly suitable
for patients with mild to moderate asthma.
Patients with mild asthma can be reluctant to use
their maintenance medication, especially when
they are relatively symptom-free. Indeed, many
consider their asthma to be a minor condition that
can be treated using reliever medication alone.3,4
Therefore, minimizing the burden of treatment is
particularly important in these patients. We com-
pared the efficacy and safety of a low dose of
budesonide/formoterol (80/4.5 mg, 2 inhalations)
administered once daily with that of twice-daily
budesonide/formoterol (80/4.5 mg, 1 inhalation
administered in the morning and the evening) and
a corresponding once-daily dose of budesonide
(200 mg, 1 inhalation in the evening) in patients
with mild to moderate asthma.Methods
Patients
Men or women agedX18 years of age were eligible
to enter this study (study code SD-039-0665) if they
had a diagnosis of asthma (minimum duration: 6
months) that was not optimally controlled despite a
daily ICS dose of 200–500 mg for at least 30 days
before study entry. Patients had a baseline forced
expiratory volume in 1 s (FEV1) of 60–90% of
predicted normal and demonstrated reversibility
of FEV1 of at least 12% upon inhalation of terbuta-
line sulfate 1mg (Bricanyls Turbuhalers; AstraZe-
neca, Lund, Sweden) or salbutamol 0.4mg.
Patients were excluded if they had: used any
systemic corticosteroids within the previous 30
days; seasonal asthma (defined as asthma exacer-
bated by seasonal increases in aeroallergens); a
respiratory infection in the 4 weeks before study
entry; a severe cardiovascular disorder or any
other significant disease; used b-blocker therapy
(including eye drops) or had a history of heavy
smoking (X10 pack-years). Women of child-bearing
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acceptable contraceptive measures were also ex-
cluded from the study. Patients who were unable to
use a peak flow meter or who did not complete the
daily diary card during 7 or more of the last 10 days
of the run-in period were not permitted to enter
the randomized treatment period.Study design
This was a randomized, double-blind, double-
dummy, active-controlled study with a parallel-
group design. It was conducted at 61 centers in
eight countries (Finland, Germany, Mexico, New
Zealand, Norway, Poland, Russia, and Sweden). The
study protocol was approved by local ethics
committees and the study was conducted in
accordance with the Declaration of Helsinki and
Good Clinical Practice Guidelines. Before entering
the study, each patient provided written informed
consent.
Patients entering the study underwent a physical
examination and provided a complete medical and
respiratory history at Visit 1. Patients then entered
a 2-week run-in period during which they received
budesonide 100 mg twice daily (Pulmicorts Turbu-
halers; AstraZeneca, Lund, Sweden). At the end of
the run-in period (Visit 2), patients were rando-
mized to receive 12-weeks’ treatment with bude-
sonide/formoterol (Symbicorts Turbuhalers;
AstraZeneca, Lund, Sweden) 80/4.5 mg 2 inhala-
tions once daily in the evening, budesonide/
formoterol 80/4.5 mg 1 inhalation twice daily, or a
corresponding dose of budesonide 200 mg 1 inhala-
tion once daily in the evening. The budesonide
doses in each group were comparable; differences
are explained by labeling changes for new inhaled
drugs, which require the delivered dose rather than
metered dose to be reported.
To ensure treatment blinding, a double-dummy
design was used so that patients received four
successively numbered Turbuhalers, with the corre-
sponding placebo inhalers being identical in appear-
ance to those containing active medication. Patients
were instructed to inhale once from the first inhaler
in the morning upon rising and to inhale once from
each of the other three inhalers in the evening just
before going to bed. They were asked to rinse their
mouths after inhaling from all inhalers. Patients
returned for clinic visits at Weeks 4, 8, and 12 of
randomized treatment (Visits 3, 4, and 5). All clinic
visits took place between 07:00 and 10:00, i.e.
within 1 h of the time that Visit 1 occurred.
Patients were given terbutaline sulfate (Brica-
nyls Turbuhalers) or another preferred short-acting b2-agonist for as-needed reliever medica-
tion. The same reliever was used throughout the
study. No other concomitant asthma medication
was allowed during the study. Patients who re-
quired a change in their asthma therapy as a
result of asthma deterioration were withdrawn
from the study.Assessments
PEF measurements, severity of asthma symptoms,
reliever medication use, intake of study drug, and
awakenings caused by asthma symptoms were
recorded by patients on diary cards. Morning and
evening PEF were measured while standing using a
Mini-Wrights peak flow meter (Clement Clark,
Harlow, UK) before intake of study medication.
On each occasion, the highest of three readings was
recorded. Patients recorded day-time and night-
time asthma symptoms (on a 4-point scale: 0 ¼ no
symptoms; 1 ¼ mild; 2 ¼ moderate; 3 ¼ severe),
together with any night-time awakenings due to
asthma symptoms and the number of reliever
medication inhalations taken during the day and
night. Patients recorded intake of their study
medication on the diary card and these data were
used to assess treatment adherence.
Lung function tests were performed at all clinic
visits. Patients were asked not to take their
morning dose of study medication before attending
the clinic and to refrain from taking any reliever
medication during the 6 h prior to lung function
testing at the clinic. Spirometry was performed
according to the European Respiratory Society
recommendations13 at each clinic visit and the
highest FEV1 values were recorded.
The following composite measures were used:
symptom-free days; reliever-free days; and asthma
control days. A symptom-free day was defined as a
day and a night with no asthma symptoms and no
night-time awakenings due to asthma. A reliever-
free day was defined as a day and a night with no
reliever medication use. These measures were
combined to determine asthma control days, which
were defined as a day and a night with no asthma
symptoms or night-time awakenings and no reliever
medication use.
Safety was assessed by recording adverse events
at Visits 2–5. Adverse events were either reported
spontaneously by the patient or in response to a
standard question asked by the investigator.
All adverse events were classified by the patient
in terms of intensity (mild, moderate, or severe).
The investigator assessed the causal relationship
between all serious adverse events and study
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rioration of asthma and asthma-related signs and
symptoms (wheeze, cough, chest tightness, dys-
pnea, breathlessness, or phlegm) were only re-
corded as adverse events if they were serious
adverse events or resulted in discontinuation of
study medication.
Analysis
All efficacy variables were analyzed on an inten-
tion-to-treat basis. The primary efficacy variable
was the mean change in morning PEF from baseline
to the end of the 12-week treatment period. It was
estimated that 130 patients were required in each
treatment group in order to detect an 18 l/min
difference between the treatments with a power
of 80% at the 5% significance level using
pairwise comparisons, assuming a standard devia-
tion of 50 l/min.
Secondary efficacy variables included evening
PEF, asthma symptoms, use of reliever medication,
night-time awakenings, and FEV1. Comparisons
between treatments were performed using analysis
of variance, with treatment and country as factors
and baseline values as covariate.
For PEF measurements and other diary card
variables, data were reduced to one baseline value
and one value on treatment (treatment mean).
Baseline values were defined as the average over
the last 10 days of the run-in period and the
treatment value was the average over the entire
treatment period. FEV1 measurements obtained at
Visit 2 were taken as the baseline value, while theTable 1 Baseline characteristics of patients.
Patient characteristic Once-daily budesonide/
formoterol (n ¼ 202)
Age (years) 45.8 (18–80)
Male/female (n) 81/121
Asthma duration (years) 11.5 (1–63)
Inhaled corticosteroid
dose (mg/day)
363 (200–500)
FEV1 (% predicted
normal)
79.3 (37–115)
Reversibility (%) 23.5 (12–91)
Morning PEF (l/min) 356 (115–684)
Evening PEF (l/min) 366 (112–670)
Night-time awakenings
due to asthma (%)
15.8 (0–100)
Symptom-free days (%) 37.8 (0–100)
Asthma control days (%) 33.9 (0–100)
FEV1, forced expiratory volume in 1 s; PEF, peak expiratory flow.V
Deviations from inclusion criteria not sufficient to warrant extreatment value was that obtained at the last clinic
visit. The percentages of symptom-free days,
reliever-free days, and asthma control days were
calculated using an additive model.Results
A total of 658 patients were enrolled in the study,
of whom 617 were randomized to treatment with
once-daily budesonide/formoterol (n ¼ 202),
twice-daily budesonide/formoterol (n ¼ 208) or
once-daily budesonide (n ¼ 207). One patient in
the twice-daily budesonide/formoterol group did
not receive any study medication; therefore, the
intention-to-treat population comprised 616 pa-
tients. A total of 61 randomized and treated
patients withdrew from the study: 26 as a result
of asthma deterioration (once-daily budesonide/
formoterol n ¼ 10, twice-daily budesonide/formo-
terol n ¼ 5, once-daily budesonide n ¼ 11); 10
as a result of other adverse events (once-daily
budesonide/formoterol n ¼ 5, twice-daily budeso-
nide/formoterol n ¼ 3, once-daily budesonide
n ¼ 2); and 25 for other reasons (once-daily
budesonide/formoterol n ¼ 6, twice-daily budeso-
nide/formoterol n ¼ 8, once-daily budesonide
n ¼ 11).
The three treatment groups were comparable
with regard to demographic and baseline charac-
teristics (Table 1). Self-reported adherence to
study medication was high, with a mean medication
use of 497% in all three treatment groups.Twice-daily budesonide/
formoterol (n ¼ 207)
Once-daily budesonide
(n ¼ 207)
43.9 (19–80) 45.1 (18–78)
78/129 91/116
12.2 (0–50) 10.6 (1–58)
371 (200–500) 368 (200–500)
77.9 (23–123) 78.3 (38–119)
23.4 (12–75) 23.2 (12–95)
351 (173–692) 358 (98–740)
362 (181–738) 371 (112–753)
14.6 (0–100) 17.9 (0–100)
36.1 (0–100) 38.1 (0–100)
32.5 (0–100) 35.1 (0–100)
alues are presented as absolute numbers or as mean (range).
cluding the patient from the study.
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Lung function
The mean increase in morning PEF from baseline
was significantly higher in the once-daily budeso-
nide/formoterol group (23.4 l/min) and the twice-
daily budesonide/formoterol group (24.1 l/min)
compared with the once-daily budesonide group
(5.5 l/min; Po0.001 for both comparisons; Table 2).
There was no significant difference between the
two budesonide/formoterol groups with regard to
the change in morning PEF. The daily mean morning
PEF values before and during treatment with
budesonide/formoterol and budesonide are shown
in Fig. 1. The difference in effect on morning PEF
between the two budesonide/formoterol groups
compared with the once-daily budesonide group
was apparent from early in the study period. The
curves for both budesonide/formoterol groups
show a rapid and large increase in morning PEF
that was maintained for the duration of the study;
as expected, the budesonide group remained at
approximately the same level throughout the study.
Evening PEF also increased significantly in the once-
and twice-daily budesonide/formoterol groups
compared with once-daily budesonide (Po0.01 for
both comparisons; Table 2).
Once- and twice-daily budesonide/formoterol
both resulted in increases in FEV1 (mean on-
treatment period) from baseline that were signifi-
cantly greater than the increase from baseline seen
with once-daily budesonide: there was a 3.8%Table 2 Effect on diary card efficacy variables of 12 wee
twice-daily budesonide/formoterol, or once-daily budeson
Efficacy variable Once-daily budesonide/
formoterol (n ¼ 202)
Increase in morning PEFa
(l/min, 95% CL)
23.4*** (18.1, 28.6)
Increase in evening PEFa
(l/min, 95% CL)
9.6** (4.4, 14.8)
Night-time awakenings
due to asthmab
(%, 95% CL)
11.3 (9.0, 13.6)
Symptom-free daysb
(%, 95% CL)
50.0* (46.0. 54.0)
Reliever-free daysb
(%, 95% CL)
61.8* (58.1, 65.4)
Asthma control daysb
(%, 95% CL)
47.3** (43.4, 51.3)
*Po0.05, **Po0.01, ***Po0.001 versus once-daily budesonide
confidence limit; PEF, peak expiratory flow.
aMean change from baseline.
bTreatment mean.difference between the two budesonide/formoter-
ol groups and budesonide (both Po0.05) (Fig. 2).
Geometric means at baseline were 2.36, 2.32,
and 2.36 l for once-daily budesonide/formoterol,
twice-daily budesonide/formoterol, and once-
daily budesonide, respectively, and the correspond-
ing 12-week values were 2.44, 2.44, and 2.35 l.Asthma symptoms
The percentages of symptom-free days, reliever-
free days and asthma control days, increased in all
three treatment groups compared with baseline,
with significantly larger increases in both once-
and twice-daily budesonide/formoterol groups
compared with the budesonide group (Table 2).
Once- and twice-daily budesonide/formoterol were
comparable for these efficacy parameters. In parti-
cular, once- or twice-daily budesonide/formoterol
treatment resulted in about 7% more asthma
control days than treatment with once-daily bude-
sonide (Po0.01) (Fig. 3). This is equivalent to 26
more days per year without day-time or night-time
asthma symptoms and without the use of reliever
medication.
Night-time awakenings during the treatment
phase were comparable between the three treat-
ment groups (Table 2) and less frequent than during
the run-in period. Although even with this improve-
ment, the patients were only completely free of
symptoms on about 50% of days.ks’ treatment with once-daily budesonide/formoterol,
ide.
Twice-daily budesonide/
formoterol (n ¼ 207)
Once-daily budesonide
(n ¼ 207)
24.1*** (19.0, 29.2) 5.5 (0.3, 10.6)
18.3***, # (13.2, 23.4) 1.7 (6.8, 3.5)
9.9 (7.7, 12.2) 12.0 (9.8, 14.3)
50.3* (46.3, 54.3) 43.4 (39.4, 47.3)
66.3*** (62.7, 69.9) 55.5 (52.0, 59.1)
47.3** (43.4, 51.1) 40.0 (36.2, 43.9)
; #Po0.05 versus once-daily budesonide/formoterol. CL,
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Figure 1 Mean change from baseline in morning peak
expiratory flow (PEF) during 12-weeks’ treatment with
budesonide/formoterol 80/4.5 mg 2 inhalations once daily
in the evening, budesonide/formoterol 80/4.5 mg 1
inhalation twice daily, or a corresponding dose of
budesonide 200 mg 1 inhalation once daily in the evening.
The solid vertical line at Day 0 represents the start of the
treatment period.
Figure 2 Forced expiratory volume in 1 s (FEV1), ex-
pressed as a percentage of the baseline value, during 12-
weeks’ treatment with budesonide/formoterol 80/4.5 mg
2 inhalations once daily in the evening, budesonide/
formoterol 80/4.5 mg 1 inhalation twice daily, or a
corresponding dose of budesonide 200 mg 1 inhalation
once daily in the evening. FEV1 was measured at clinic
visits (Visit 2 ¼ randomization visit [Week 0]; Visit
3 ¼ Week 4; Visit 4 ¼ Week 8; Visit 5 ¼ Week 12). The
solid vertical line at Day 0 represents the start of the
treatment period.
Figure 3 Mean change from baseline in asthma control
days during 12-weeks’ treatment with budesonide/
formoterol 80/4.5 mg 2 inhalations once daily in the
evening, budesonide/formoterol 80/4.5 mg 1 inhalation
twice daily, or a corresponding dose of budesonide 200 mg
1 inhalation once daily in the evening. An asthma control
day was defined as a day and night with no asthma
symptoms, no night-time awakenings, and no reliever
medication use. The solid vertical line at Day 0
represents the start of the treatment period.
P. Kuna et al.2156Safety
All treatments were well tolerated. Seventy-six
patients (38%) in the once-daily budesonide/for-
moterol group, 78 patients (38%) in the twice-daily
budesonide/formoterol group, and 74 patients
(36%) in the once-daily budesonide group experi-
enced at least one adverse event. The number and
nature of the adverse events were similar across all
three treatment groups. The most frequently
reported adverse events are presented in Table 3.
Seven serious adverse events were reported: two
in the once-daily budesonide/formoterol group,
one in the twice-daily budesonide/formoterol
group, and four in the once-daily budesonide group.
These were asthma aggravated (n ¼ 3), acute
vertigo (n ¼ 1), lung carcinoma (n ¼ 1), chest pain
(n ¼ 1), and thyroiditis (n ¼ 1). None was consid-
ered to be related to study treatment.Discussion
In this study, we have shown that once-daily
budesonide/formoterol provides a rapid and sus-
ARTICLE IN PRESS
Table 3 Most frequently reported adverse events (occurring in X2% of patients in any treatment group).
Adverse event No. of patients (%)
Once-daily budesonide/
formoterol (n ¼ 202)
Twice-daily budesonide/
formoterol (n ¼ 207)
Once-daily budesonide
(n ¼ 207)
Respiratory infection 23 (11.4) 32 (15.5) 25 (12.1)
Asthma aggravated 12 (5.9) 6 (2.9) 10 (4.8)
Viral infection 6 (3.0) 7 (3.4) 5 (2.4)
Pharyngitis 4 (2.0) 7 (3.4) 5 (2.4)
Rhinitis 4 (2.0) 4 (1.9) 4 (1.9)
Bronchitis 2 (1.0) 6 (2.9) 3 (1.4)
Headache 4 (2.0) 4 (1.9) 2 (1.0)
Pharynx disorder 4 (2.0) 2 (1.0) 1 (0.5)
Once-daily budesonide/formoterol in mild to moderate asthma 2157tained improvement in lung function measured as
morning PEF, similar to twice-daily budesonide/
formoterol, in patients with mild to moderate
asthma who were not fully controlled on ICS alone.
This was achieved using a low dose of ICS/long-
acting b2-agonist (80/4.5 mg budesonide/formoter-
ol, 2 inhalations in the evening). Patients treated
with once-daily budesonide/formoterol also
showed improvements in FEV1, symptom-free days,
reliever medication use, and the composite mea-
sure of asthma control days, compared with
budesonide. These changes were comparable with
the improvements observed in patients treated
with twice-daily budesonide/formoterol, and were
significantly better than for patients treated with
once-daily budesonide alone.
We used the composite measure of asthma control
days in order to capture the effect of treatment on a
variety of outcomes relevant to patient quality of
life. All patients had an increase in asthma control
days, which can be attributed in part to the
improved adherence and more intensive clinical care
that result from being in a clinical trial. The increase
in asthma control days per year was equal in patients
treated with once- and twice-daily budesonide/
formoterol and translates into 26 additional days of
asthma control compared with patients receiving
budesonide alone. This is an important benefit that
patients can perceive and has the potential to
improve adherence to treatment.
Improvements in morning PEF were observed
earlier in both the once- and twice-daily budeso-
nide/formoterol groups, compared with the bude-
sonide group. This is in line with results from the
study by Zetterstro¨m et al.,5 who reported that
improvements in morning PEF were significantly
greater on Day 1 of the study in patients treated
with budesonide/formoterol compared with bude-
sonide alone (Po0.001). This is likely to be due to
the bronchodilatory effect of the formoterolcomponent.14 It should be acknowledged that the
patients were required to have at least 12%
bronchodilator reversibility in order to take part
in the study. This inclusion criterion was necessary
to confirm the diagnosis of asthma, but may have
increased the likelihood that patients would re-
spond to the addition of inhaled formoterol as part
of their treatment regimen.
Once-daily budesonide/formoterol showed sus-
tained efficacy that was comparable with that of
twice-daily budesonide/formoterol. Although im-
provements in morning PEF were very similar in the
two budesonide/formoterol groups, patients in the
twice-daily budesonide/formoterol group had
greater improvements in evening PEF than those
in the once-daily dosing group. However, symp-
toms, reliever medication use, and night-time
awakenings were similar for the once-and twice-
daily budesonide/formoterol groups, indicating
that control was maintained throughout the day
with once-daily treatment.
While many studies have demonstrated the
safety and efficacy of once-daily dosing with
ICS,15,16 once-daily dosing with the combination
of an ICS and a LABA is less well investigated. To the
best of our knowledge, ours is only the second study
to examine the safety and efficacy of once-daily
ICS/LABA, the other being the study by Buhl et al.12
The participants in our study had less severe
asthma than those in the Buhl et al. study as
demonstrated by the lower dose of inhaled steroid
that they were using prior to entry into the study
(367, vs. 610 mg, respectively) and we were able to
demonstrate the benefits of once-daily budeso-
nide/formoterol with half the dose of inhaled
steroid that was used in the study by Buhl et al.
Taken together, these studies demonstrate that
once-daily dosing with budesonide/formoterol is an
effective treatment for patients with a range of
asthma severities.
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possible because of the pharmacologic properties
of the two components. Formoterol (24 mg) has
been shown to have a protective effect against the
late-phase asthmatic response to allergen chal-
lenge that is maintained for 32 h.17 A standard dose
of formoterol (12 mg via metered-dose inhaler
corresponds to 9 mg via Turbuhaler) was found to
have a 24-h duration of bronchodilation and
attenuation of airways hyperresponsiveness.18 The
duration of action of formoterol therefore appears
to be in excess of the 12 h reported previously.19,20
Budesonide has a prolonged antiinflammatory ef-
fect compared with other ICS as it undergoes
esterification in the lung and bronchial cells, which
increases drug retention in the airways.21,22 After
saturation of the glucocorticoid receptor in airway
cells, excess budesonide is converted to an inactive
intracellular ester pool in a rapid, reversible
esterification reaction. As intracellular concentra-
tions of budesonide decline, the reaction is
reversed and active budesonide is released. This
prolongs the local effects of budesonide and so may
explain why once-daily budesonide has been shown
to be effective in adults and children with mild to
moderate asthma.23–29
Achieving optimal frequency of dosing has im-
portant implications for adherence to prescribed
medication, as compliance is reduced with in-
creased frequency and complexity of treat-
ment.11,30,31 Most of the evidence for improved
adherence with once-daily dosing comes from
studies with oral medication but the importance
of reduced dosing frequency should not be under-
estimated in patients with mild asthma, who may
perceive their condition to be a minor one and
consequently may not adhere to ICS regimens
during periods of good control.32 Indeed, patients
with mild asthma showed a significant preference
for a once-daily dosage regimen of budesonide
compared with twice-daily fluticasone, and 61%
said they would prefer to use a once-daily regimen
given the choice.28 This is supported by results of a
recent market research survey, in which 85% of
those questioned said they would prefer simpler
regimens using fewer drugs for their asthma.4
These findings suggest that once-daily dosing with
a combination of an inhaled steroid and a long-
acting inhaled b2-agonist will improve adherence
but there have been few studies that have looked
directly at this question and we hope that our
findings will promote more research in this area.
Patients’ safety concerns may also affect their
adherence to ICS33 and many patients tend to rely
on their reliever medication to treat their asthma
symptoms,3 while neglecting to treat the under-lying inflammation. Providing patients with a
convenient to use, effective medication may
contribute to improved adherence and better
long-term asthma control.
In conclusion, once-daily low-dose budesonide/
formoterol (80/4.5 mg, 2 inhalations) in the evening
is as effective in improving asthma control and as
well tolerated as the same daily dose of budeso-
nide/formoterol administered twice daily in pa-
tients who were not optimally controlled on ICS
alone. The simplicity of this treatment strate-
gy—one inhaler used once daily—may have the
potential to improve adherence to therapy.Acknowledgements
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